Market capitalization | $54.56m |
Enterprise Value | $17.16m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.33 |
P/S ratio (TTM) P/S ratio | 4.23 |
P/B ratio (TTM) P/B ratio | 1.05 |
Revenue growth (TTM) Revenue growth | 16.84% |
Revenue (TTM) Revenue | $12.89m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
4 Analysts have issued a Hyperfine forecast:
4 Analysts have issued a Hyperfine forecast:
Dec '24 |
+/-
%
|
||
Revenue | 13 13 |
17%
17%
|
|
Gross Profit | 5.89 5.89 |
24%
24%
|
|
EBITDA | -42 -42 |
10%
10%
|
EBIT (Operating Income) EBIT | -43 -43 |
10%
10%
|
Net Profit | -41 -41 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hyperfine, Inc. is a medical device development company, which is engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.
Head office | United States |
CEO | Maria Sainz |
Employees | 111 |
Founded | 2014 |
Website | www.hyperfine.io |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.